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Hepatic encephalopathy (HE) represents a wide spectrum of neurological or 
neuropsychological symptoms due to liver disease and/or portosystemic shunts. The major 
role of hyperammonemia in association with systemic inflammation and oxidative stress has 
progressively emerged as key players in the pathogenesis of HE. However, the cascading 
downstream effects due to these pathogenic factors remain unresolved. The underlying 
abnormalities which have been described to cause HE include modification of glutamatergic 
and GABAergic neurotransmission, mitochondrial dysfunction, energy impairment, lactate 
dyshomeostasis, increased blood-brain barrier permeability, brain edema/astrocyte swelling as 
well as accumulation of toxic compounds (manganese, bile acids, indols) [1]. Abnormal 
cerebral blood flow (CBF) and cerebral metabolic rate of oxygen (CMRO2) have also been 
described and extensively discussed in their involvement  in the pathogenesis of HE [2,3]. 
Due to the high metabolic activity of the brain, it demands close to 20% of whole 
body’s total oxygen consumption, with a large proportion of CMRO2 being used to maintain 
and restore membrane potentials. CMRO2 can be calculated using 
15
O-oxygen positron 
emission tomography (PET) and 3.5-5 mL/100g brain tissue/min is the physiological range 
measured in healthy individuals [4]. CBF, corresponding to the quantity of blood supplied to 
the whole brain in a determined period of time, can be assessed using 
15
O-water PET.  
Magnetic resonance imaging (MRI) techniques can also, indirectly, estimate CBF but with a 
lower reproducibility. In healthy individuals, CBF is approximately 50 mL/100g brain 
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tissue/min [5]. It is also possible to evaluate the regional cerebral blood perfusion with both 
15
O-water PET and MRI, arterial spin labelling sequences or functional MRI, the former using 
blood oxygenation level dependent (BOLD) effect to evaluate regional consequences on 
perfusion of a specific cognitive task [5]. Cerebral autoregulation is the maintenance of 
constant CBF despite changes in systemic blood pressure where a cerebral vascular tone 
adaptation exists which adjusts the regional blood perfusion following increased oxygen 
demand in certain areas of the brain. Thus, in a healthy adult (normotensive), CBF does not 
alter following changes in mean arterial pressure (MAP) between 50 to 150 mmHg. As 
suggested by Poiseuille’s law, CBF is inversely related to the radius of vessels to the power 
four, therefore, this physiological response occurs merely with a minor adjustment in the 
vascular resistance/tone, and thus in the diameter of large arteries and parenchymal arteries. 
Outside the range of autoregulation (MAP <50 mmHg or > 150 mmHg) the CBF is 
compromised and can consequently cause cerebral anoxia-ischemia or vasogenic (cerebral) 
edema (posterior reversible encephalopathy syndrome) [6]. Several cellular mechanisms and 
factors have been proposed to be implicated in the conservation of CBF autoregulation: 
sympathic and parasympathic innervation, levels of PaCO2 and PaO2, release of H
+
, K
+
, 
endothelial vasoactive factors such as nitric oxide, calcitonin related peptide and adenosine 
[7]. 
With 
15
O-water PET, it has been shown that CBF does not significantly differ between 
cirrhotic patients and healthy subjects. However, in cirrhotic patients with overt HE CBF was 
found to be significantly less (approximately 66% of normal values) [2,8] which was 
demonstrated in patients with minimal HE [9]. More specifically, reduced regional CBF has 
been reported in the parietal cortex, occipital cortex and thalamus in overt HE patients [8]. In 
this context, it appears a reduction in CBF is solely associated with overt HE as CBF in 
patients with minimal HE was similar to cirrhotic patients (without HE) and healthy controls 
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[9]. However, increased regional CBF has been demonstrated using MRI in the basal ganglia 
and thalamus in patients with minimal HE when compared to healthy controls which was 
interpreted as a redistribution of CBF from the cortex to the diencephalon [10]. Interestingly, 
in patients having received a transjugular intrahepatic portosystemic shunt (TIPS), a decrease 
in CBF was found in patients that developed overt HE [11]. Using functional MRI, it was 
demonstrated that cirrhotic patients with minimal HE had abnormal regional CBF in several 
brain regions when performing different cognitive tasks (as reviewed by Keiding [4]). Parallel 
with CBF, similar findings were found with CMRO2 using 
15
O-oxygen PET and a positive 
relationship between CMRO2 and CBF was shown during and after recovery from HE within 
individual patients [2,12]. Patients with overt HE had decreased CMRO2, about 66% normal 
values, compared to cirrhotic patients without HE or healthy controls [8]. Regional 
differences were also demonstrated in CMRO2 with reduction in the occipital and parietal 
cortex, and in areas of the thalamus, striatum, frontal cortex, temporal cortex and frontal parts 
of the cingulate cortex. Previously, it was suggested that a decrease in CMRO2 was a result of 
a reduced oxygen supply. However, more recent studies have showed that the reduced 
CMRO2 in patients with HE is not caused by limitation of the oxygen supply but rather 
reflects a decline in oxidative metabolism with a secondary reduction in CBF. Additionally, 
analysis of flow-metabolism coupling indicated that CBF declined in HE as a consequence of 
reduced brain energy metabolism implied by the calculation of increased mitochondrial 
oxygen tensions that patients with HE were unable to utilize [12]. Therefore, it is understood 
that there is no oxygen delivery limitation in HE [12]. A possible inverse relationship between 
CMRO2 and cerebral ammonia uptake has been previously suggested. However, this was 
challenged when it was demonstrated that an increase in CMRO2 occurred following recovery 
from HE with no significant change in the cerebral metabolic rate of ammonia (CMRA). 
Furthermore, neither CMRO2 nor CBF were related to the arterial ammonia concentration or 
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CMRA within individual patients [2]. Nevertheless, these findings using PET with only 
limited number of patients, does not exclude ammonia as a causal agent of energy impairment 
as it has been recently demonstrated that patients with HE have altered levels of glutamine 
and alpha-ketoglutarate in the cerebrospinal fluid [14]. 
In this issue of the journal, Bjerring et al. [15] elegantly demonstrated using cranial 
windows in anesthetized rats that exposing the brain to ammonium chloride leads to an 
increase in flow velocities of cerebral arterioles (using speckle contrast imaging), arteriolar 
surface area with an increase in periarteriolar concentration of adenosine (using biosensors 
inserted in the cortex). Furthermore, ammonia exposure also impaired preservation of flow 
(cerebral autoregulation) during hemorrhagic hypotensive challenge. Applying ZM241385 
(adenosine receptor antagonist) leads to restoration of cerebral autoregulation flow partially 
restoring to baseline values. Adenosine is a nucleoside present in the cerebral extracellular 
space that is mainly formed by ATP degradation that can directly activate four membrane 
receptors subtypes: A1, A2A, A2B and A3 and is implicated in cyclic AMP production [16]. 
The activation of A1 could be neuroprotective through a specific action on neurons by 
blocking the excitotoxic glutamate release and the intracellular increase in calcium levels. 
A2A is constitutively expressed in the central nervous system and acts by activating adenylate 
cyclase, enhancing glutamate release and GABAergic activity in striato-pallidal neurons 
[16,17]. A2A receptor could interact with dopamine receptor D2 and as a result, currently 
blocking A2A receptor strategies are being evaluated for a treatment in Parkinson disease [18]. 
A1, A2A can be activated only by micromolar concentration of adenosine which only arise 
during pathological conditions;  it can increase up to a thousand fold following cerebral 
ischemia or hypoxia (20).  
The results from the study of Bjerring et al., suggest that even if CMRO2 is not 
directly linked to ammonia levels, elevated ammonia is able to increase flow velocities and 
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perhaps CBF via an increase in adenosine tone. These findings are in accordance with results 
showing that systemically administered adenosine had a direct cerebral vasodilatory effect 
and altered cerebral autoregulation in an induced hypotension pig anesthetized model which 
both resolved following adenosine removal [21]. Administration of A2A adenosine receptor 
antagonist, ZM241385, has also been shown to be able to shift the lower limit of cerebral 
autoregulation to higher blood pressure and to suppress the vasodilation of pial arteries in 
response to hypotension [22]. Bjerring and colleagues elegantly demonstrated the importance 
of adenosine in CBF. However, the mechanisms through which ammonia triggers adenosine 
release remain unknown. It could be speculated that ammonia toxicity could impact on 
adenosine metabolism (generation and breakdown), possibly implicating ATP utilization. It is 
important to note, the animal models involved in the above studies are not models of liver 
failure or disease and therefore more extensive data arising from animal models of liver 
failure/disease are highly warranted. 
The paper from Bjerring et al., describes another important issue proposing that A2A 
receptor antagonist ZM241385 could be used to treat HE. Most treatment strategies for HE 
target a blood-derived factor, especially ammonia [23]. Centrally acting drugs that directly 
target the brain are sparse and except for flumazenil [24], none have been extensively used in 
patients. This could largely explain some limitations in the treatment strategies in HE. 
Recently, a GABAA receptor modulating steroid antagonist (GAMSA), has been developed 
and act as antagonists to the positive GABAA receptor, thereby modulating the effects of the 
neurosteroids. The reduction in the activity of the inhibitory GABAergic system may benefit 
arousal and cognition [25]. However, targeting the brain requires crossing the blood-brain 
barrier as well as avoiding any peripheral action (unwanted secondary effects) due to the use 
of major systemic drug concentration [26]. Interestingly, a very common A2A receptor 
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antagonist, caffeine, has been used with interesting results in simulated hyperammonemia in 
cirrhotic patients [27,28]. 
Patients with cirrhosis can be exposed to hypotensive insults; upper gastrointestinal 
bleeding (GIB) as well as perioperative conditions during liver transplantation. GIB 
constitutes a major risk factor for HE and preventive treatment strategies are being proposed. 
Liver transplantation is the solid-organ transplantation that is associated with the highest 
frequency of neurological post-operative complications (approximately 1/3 of transplanted 
patients) due to different factors including  perioperative hypotension [29,30]. Indeed, it could 
be assumed that hyperammonemia could have an additive or even a synergistic effect with 
hypotension in these patients.  
Hyperammonemia leads to increased brain ammonia and subsequently neurotoxicity 
which is induced through a different cellular pathways and mechanisms, including adenosine 
release and activation as described by Bjerring and al., in this issue. Therefore, lowering 
ammonia remains the primary treatment strategy. Recent developments of ammonia lowering 
agents are primarily being tested and used for the acute treatment of overt HE [31,32]. 
However, long-term studies are required to evaluate whether attenuating hyperammonemia 
could reduce the incidence of overt HE after GIB or the incidence of post-operative 
neurological complications after liver transplantation. Interestingly, ammonia has recently 
been identified as a prognostic factor in patients with end-stage liver disease [33,34]. 
Furthermore, ammonia has been shown to be involved in the development of sarcopenia [35] 
as well as possibly playing a role in acute-on-chronic liver disease [36].    
Therefore, realizing the toxic effects of ammonia are not specific to the brain [37] and 
that ammonia can act as a metabolic stressor [38], the implication of hyperammonemia in the 
onset of complications in cirrhosis is just beginning.  
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